Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
MRNA · against 44 other Healthcare companies of similar size
Ranked #14 of 45 · scores higher than 70% of peers · safety percentile 45
Bars: peers in each 10-point band of the safety percentile (higher = safer; 67+ earns the lower-risk grade)2 peers with a safety percentile of 40–49, including MRNA · Click a bar to see the companies
Its metrics sit close to the Healthcare norm.
Risk is relative to the sector, not a bankruptcy probability. Banks and brokers carry high leverage by design, and share buybacks can shrink equity and current assets, which raises debt/equity on paper.
| Metric | MRNA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Debt / equityLower is better · 40 reported | 0.19× | 0.56× | 72% | 33% | |
| BetaLower is better · 43 reported | 1.09 | 0.55 | 12% | 33% | |
| Current ratioHigher is better · 43 reported | 2.29× | 1.53× | 74% | 33% |
| Rank | Company | Market cap | Safety | Overall |
|---|---|---|---|---|
| 1 | 327.3B CNY (≈$45.8B) | 92 | 75 | |
| 2 | 56.7B USD | 85 | 79 | |
| 3 | 8.24T JPY (≈$56.0B) | 83 | 75 | |
| 4 | 4.25T INR (≈$51.0B) | 81 | 70 | |
| 5 | 100.2B USD | 77 | 68 | |
| 10 | 67.60T KRW (≈$48.7B) | 64 | 72 | |
| 11 | 534.1B HKD (≈$68.4B) | 58 | 75 | |
| 12 | 52.7B EUR (≈$58.0B) | 52 | 71 | |
| 13 | 108.6B USD | 51 | 66 | |
| 14 | 91.2B USD | 45 | 18 | |
| 15 | 155.7B USD | 43 | 64 | |
| 16 | 84.5B EUR (≈$92.9B) | 37 | 51 | |
| 17 | 56.0B USD | 37 | 39 | |
| 18 | 126.5B USD | 37 | 56 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score